Because Merck has not applied for the substance patent of natural series of cryptoalgae in China, this project plans to use natural cryptoalgae to conduct preclinical test in China, including redoing part of pharmacodynamics and toxicology research of natural cryptoalgae, so as to enter the clinical research as soon as possible.

With unique efficacy, high safety, simple preparation, low dosage, simple production process and quality control, the natural cryptoalgin series is expected to become a new class of bioengineering drugs with great market value and strict protection of intellectual property rights.

Due to China's accession to the WTO, under the circumstances that the imitation of foreign new drugs is limited at present, and the innovation ability of Chinese new drugs is impossible to achieve a breakthrough in the near future, it is of great significance to legally introduce such special projects as cryptoalgae, which have been abandoned by large foreign pharmaceutical enterprises due to patent rights disputes. This mode can obtain the exclusive production and marketing rights of the drug in China at a low cost, and can greatly speed up the research and development of new drugs;

More importantly, through close international cooperation, we can make full use of foreign knowledge and experience, reduce detours, enhance the ability of technological innovation and product innovation, and gradually form our country's advantageous technology and products in the field of medicine. With the increasing attention and investment of Chinese government and enterprises in the development of new drugs, cryptoalgae, a special project with great demonstration significance, will be strongly supported by governments and enterprises at all levels.
The cryptoalgal research group of the University of Hawaii has a complete set of laboratories and corresponding research teams. It has been engaged in the preparation of cryptoalgal by biosynthesis, semi synthesis and total synthesis for a long time, and has studied the relationship between the chemical structure and physiological activity of cryptoalgal in detail.

The research and development work of the University of Hawaii in the early stage has used more than $3 million. The cryptoalgin research group now has $200000 for related research and development work. The University of Hawaii will invest another $70000 in July this year, and another $50000 special fund will be put in place in July this year. Due to the maximum use of foreign funds and resources, the amount of investment needed to seek domestic has been reduced a lot.

The investment company is required to invest 5 million yuan in one time for preclinical (and early clinical) trials in China. It is estimated that it will obtain the approval of clinical trials issued by the State Food and Drug Administration (SFDA) within 1-2 years. It is planned to complete the clinical trial by applying for funding from governments at all levels and various foundations in China and the United States. The shares held by all parties remain unchanged.

In case that the funds are not in place in time and may affect the progress of the clinical trial, the investment company may make additional investment according to the actual needs of the project, but the additional capital shall not exceed fifteen million yuan;

At the same time, the technical side can also raise additional funds for the development of large-scale production of cryptoalgin technology, and the production of drugs for clinical trials. These costs should also be used as the investment of the technical side. The specific investment matters shall be confirmed by a separate agreement signed by both parties.
After obtaining the clinical trial approval issued by SFDA, it is expected that the transfer price of the clinical approval of cryptoalgae is more than 25 million yuan, and the investment company can choose to transfer the shares at this time to withdraw. It will take about 4 years to complete the clinical trial and obtain the new drug certificate, and the price of transferring the new drug certificate is expected to be more than 100 million yuan.

|||Cryptoalgin C-1 is a kind of small molecular polypeptide drug selected and isolated from cyanobacteria by the University of Hawaii for the treatment of drug-resistant malignant solid tumors. The compound, especially its derivatives, can well distinguish cancer cells from normal cells, so as to selectively kill cancer cells.

In the in vivo experiment, some derivatives of cryptoalgin are much better than all the anticancer drugs in clinical use (such as paclitaxel, adriamycin, vinblastine, camptothecin, etoposide, etc.). NSF, NIH, NCI and other units have provided long-term and large amount of special fund support for this research, and relevant research progress and results have also passed the formal regular review of various expert groups organized by these units.

In addition, research groups around the world have also confirmed and expanded the physiological activity in vitro and antitumor activity in vivo of cryptoalgin and its derivatives. |||It's very professional. Please ask the biomedical experts to help. You can also consult the relevant scientific research institutes. They are very professional. Please ask the biomedical experts to help you.
We can also consult the related small molecule polypeptides for the treatment of drug-resistant solid tumors. Cryptoalgin C-1 is a kind of small molecule polypeptides for the treatment of drug-resistant solid tumors screened and isolated from cyanobacteria by the University of Hawaii. This compound, especially its derivatives, can well distinguish cancer cells from normal cells, so as to selectively kill cancer cells.

In the in vivo experiment, some derivatives of cryptoalgin are much better than all the anticancer drugs in clinical use (such as paclitaxel, adriamycin, vinblastine, camptothecin, etoposide, etc.). NSF, NIH, NCI and other units have provided long-term and large amount of special fund support for this research, and relevant research progress and results have also passed the formal regular review of various expert groups organized by these units.

In addition, research groups around the world have also confirmed and expanded the physiological activity in vitro and antitumor activity in vivo of cryptoalgin and its derivatives.

Cryptoalgin stands out from a large number of candidate compounds with its outstanding anti drug activity. It was purchased by Lilly, one of the top ten pharmaceutical companies in the world, for its exclusive patent right. In order to avoid paying Merck's huge material patent fees, Lilly had to give up the development of natural series of cryptoalgae C-8;

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.